Clinical Trials Browser

Phase 2 × OTHER × Rifaximin × Clear all

NCT04249622 2025-09-16

Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer

Phase 2 Terminated

20 enrolled 13 charts

Anatomic Stage I Breast Cancer AJCC v8

NCT05502913 2023-10-02

Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer

Phase 2 Recruiting

Lung Neoplasms